JPMorgan lowered the firm’s price target on Biogen (BIIB) to $175 from $185 and keeps a Neutral rating on the shares. The analyst updated the company’s model post the Q1 report.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen’s Hold Rating: Balancing New Drug Growth with Declining MS Franchise and Safety Concerns
- Biogen’s International Growth and Promising Pipeline Drive Buy Rating
- Biogen price target lowered to $205 from $255 at Oppenheimer
- Biogen price target lowered to $205 from $217 at RBC Capital
- Biogen price target lowered to $146 from $152 at Morgan Stanley
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue